The aim of the present study was to evaluate the prognostic significance of BCL-2 expression in the group of 172 women with breast cancer in clinical stage T1–T2, N1–N2, M0, treated with ATC in adjuvant settings. This evidence concerns the gene BCL2 and breast cancer.